Paradigm Biocapital Advisors »

SPDR S&P Biotech shares owned by Paradigm Biocapital Advisors

Quarter-by-quarter ownership of SPDR S&P Biotech (XBI) shares owned by Paradigm Biocapital Advisors from 13F filings

Historical chart of Paradigm Biocapital Advisors investment in SPDR S&P Biotech

Tip: Access up to 7 years of quarterly data

All positions including SPDR S&P Biotech held by Paradigm Biocapital Advisors consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in SPDR S&P Biotech by Paradigm Biocapital Advisors

Quarter filed Position value Share count Share price at filing
2025-09-30 $100M 1.0M 100.20

More positions owned by Paradigm Biocapital Advisors

Nuvalent Inc-a (NUVL)
Merus N V Call Option (MRUS)
Arcellx Common Stock (ACLX)
Revolution Medicines (RVMD)
Tarsus Pharmaceuticals (TARS)
Vaxcyte (PCVX)
Abivax Sa Sponsored Ads (ABVX)
Genmab A/s Sponsored Ads (GMAB)
Agios Pharmaceuticals Call Option (AGIO)
Crinetics Pharmaceuticals In (CRNX)
Spdr Series Trust S&p Biotech Put Option (XBI)
Edgewise Therapeutics (EWTX)
Cidara Therapeutics Com New (CDTX)
Urogen Pharma (URGN)
Scholar Rock Hldg Corp (SRRK)

View all positions for Paradigm Biocapital Advisors

Top funds holding SPDR S&P Biotech

Goldman Sachs Group
Healthcare Of Ontario Pension Plan Trust Fund
Jpmorgan Chase & Co
Morgan Stanley
Susquehanna International
Citadel Advisors
Jane Street
Bnp Paribas Arbitrage, Snc
Millennium Management
Peak6
UBS Group
Wells Fargo & Company
Barclays
Balyasny Asset Management
Canada Pension Plan Investment Board

View all funds holding SPDR S&P Biotech